ImageneBio opened higher at $3.83, compared with its previous close of $3.72. In the last trading session, the stock traded between $3.44 and $3.83. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in ImageneBio is now worth
$ 20.80
Resulting in a loss of
$ 79.20 (79.20%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.32 (-8.47%)
Day High
$3.83
Day Low
$3.44
Day Open
$3.83
Prev Close
$3.72
Volume
10,628
1W Return
-15.93%
1M Return
-18.87%
3M Return
-38.32%
6M Return
-39.30%
1Y Return
-60.45%
Fundamentals
Market Cap ($ Mn)
39
PE Ratio
-
PB Ratio
0.42
PEG Ratio
-
ROE
-145.60%
ROCE
-49.35%
EPS (TTM)
-
Investment Returns
1 Week
-15.93%
1 Month
-18.87%
3 Months
-38.32%
6 Months
-39.30%
9 Months
-51.50%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
10Nov
ImageneBio Q3 Results: Loss per share narrows 68.73% YoY
ImageneBio reported a Q3 loss of $(0.91) per share, missing the analyst estimate of $(0.83) by 9.64%. The loss narrowed by 68.73% year-over-year from $(2.91) in the prior year. Analysts had expected a smaller loss, indicating a slight underperformance relative to consensus.
3 days ago
3Oct
ImageneBio grants 123,500 shares and options to new hires
Granted 90,775 RSUs and 32,725 NSOs to three new non-executive employees. Stock options priced at $4.58 per share based on Sept 30, 2026 closing price. Awards issued under Nasdaq Listing Rule 5635(c)(4) as employment inducements.
1mo ago
9Sep
ImageneBio CEO to present at H.C. Wainwright conference on Sept. 14
ImageneBio CEO Kristin Yarema will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York. The fireside chat is scheduled for Monday, Sept. 14, 2026, at 3:30 pm ET. Management will also participate in one-on-one meetings at the conference. The webcast will be archived for 90 days on the Imagene investor relations website. ImageneBio is a clinical-stage biotechnology company with an ongoing Phase 2b trial of olevaprubart in moderate-to-severe atopic dermatitis.
2mo ago
18Aug
ImageneBio grants equity inducements to CFO and three new hires
ImageneBio granted equity inducements to CFO Yanina Grant-Huerta and three new hires under Nasdaq Rule 5635(c)(4). The awards include RSUs and NSOs with a $5.84 exercise price, vesting over four years based on continuous service. Grant-Huerta also received additional RSUs under the 2025 Equity Incentive Plan.
2mo ago
7Jul
ImageneBio appoints Matt Robbins as General Counsel
ImageneBio, Inc. has appointed Matt Robbins as General Counsel, effective July 7, 2026. Robbins will oversee legal, governance, IP, and compliance functions, bringing extensive experience from his roles at Bright Peak Therapeutics, Inc. and Cooley LLP. The appointment supports ImageneBio's advancement of its lead candidate, IMG-007, through Phase 2 clinical programs in atopic dermatitis and alopecia areata.
